麦格理发表研报指，维他奶(00345.HK) 2025财年上半年营业利润按年升50%，主要由于严格的广告及促销控制及营业杠杆，抵销了澳州及新西兰业务的营业亏损。期内，维他奶中国内地及香港的经营利润率，分别改善至11.1%及13.8%，集团管理层目标分别是恢复至16%及19%的高峰水平。
麦格理表示，考虑到维他奶审慎的营运开支，故将其2025财年净利润预测上调14.6%。不过鉴于营收增长前景较为温和，故同时将2026及2027财年净利润预测，分别下调2.2%及5.4%。
麦格理将维他奶目标价上调55%至10.7元，此相当于预测2026财年市盈率20倍，给予“跑赢大市”评级。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-11-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.